Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (7)
  • Open Access

    ARTICLE

    miR-181a Inhibits Cervical Cancer Development via Downregulating GRP78

    Chengyan Luo, Jiangnan Qiu

    Oncology Research, Vol.25, No.8, pp. 1341-1348, 2017, DOI:10.3727/096504017X14867268787969

    Abstract Cervical cancer is among the most common cancers inflicting women worldwide. Understanding the pathological mechanisms of cervical cancer development is critical for identifying novel targets for cervical cancer treatment. MicroRNAs (miRs) have various roles in regulating cancer development. In this study, we investigated the potential role of miR-181a and its target in regulating cervical cancer development and chemotherapy resistance. The expression of miR-181a was evaluated and modulated in several human cervical cancer cell lines. The role of miR-181a in regulating cervical cancer growth and chemotherapy sensitivity was investigated in cell culture models and mouse tumor… More >

  • Open Access

    ARTICLE

    Targeted Silencing of Kim-1 Inhibits the Growth of Clear Cell Renal Cell Carcinoma Cell Line 786-0 In Vitro and In Vivo

    Jianping Xu, Liguo Sun, Wei Sun, Jianhai Tian, Huaiyuan Guo

    Oncology Research, Vol.26, No.7, pp. 997-1003, 2018, DOI:10.3727/096504017X15140544654946

    Abstract To investigate the effect of Kim-1 on 786-0 cells in vivo and in vitro, several experiments such as quantitative real-time PCR, Western blot, MTT, colony formation, and flow cytometry were performed to evaluate the biological behavior of 786-0 cells treated with Kim-1 siRNA. Furthermore, the tumor xenograft model was applied to BALB/c nude mice to assess the effect of Kim-1 silencing. Lentivirus-mediated RNAi effectively silenced Kim-1 in 786-0 cells. Kim-1 knockdown significantly inhibited the proliferation and colony formation ability of 786-0 cells (p < 0.01). The cell cycle of 786-0 cells was arrested in the G0/G1 phase (p < More >

  • Open Access

    ARTICLE

    Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients

    Yuping Shen, Chunyan Li, Weixing Liu, Wei Mao, Hong Qian, Hui Wang, Qing Xu

    Oncology Research, Vol.26, No.5, pp. 801-807, 2018, DOI:10.3727/096504017X15139039328978

    Abstract This study investigated the characteristics of oxaliplatin-induced hypersensitivity reactions (HSRs) and evaluated the efficacy of premedication for controlling HSRs among colorectal cancer patients. A retrospective study was performed on the clinical records of 291 patients with colorectal cancer in The Tenth People’s Hospital of Shanghai from January 2008 to January 2016. Patients who experienced HSRs to oxaliplatin were compared with those who did not. A total of 291 colorectal cancer patients received oxaliplatin, with 39 (13.40%) experiencing HSRs. Oxaliplatin-free interval and premedication with dexamethasone and antihistamine were independent variables for oxaliplatin-related HSRs. Rechallenging patients with More >

  • Open Access

    ARTICLE

    A novel oxaliplatin-resistant gene signatures predicting survival of patients in colorectal cancer

    QIOU GU1, CHUILIN LAI1, XIAO GUAN1, JING ZHU2, TIAN ZHAN1, JIANPING ZHANG1,*

    BIOCELL, Vol.48, No.2, pp. 253-269, 2024, DOI:10.32604/biocell.2023.028336

    Abstract Objectives: Colorectal cancer (CRC) is a serious threat to human health worldwide. Oxaliplatin is a platinum analog and is widely used to treat CRC. However, resistance to oxaliplatin restricts its effectiveness and application while its target recognition and mechanism of action also remain unclear. Therefore, we aimed to develop an oxaliplatin-resistant prognostic model to clarify these aspects. Methods: We first obtained oxaliplatin-resistant and parental cell lines, and identified oxaliplatin-resistant genes using RNA sequencing (RNA-seq) and differential gene analysis. We then acquired relevant data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases.… More > Graphic Abstract

    A novel oxaliplatin-resistant gene signatures predicting survival of patients in colorectal cancer

  • Open Access

    HOXB8 contributed to oxaliplatin chemo-resistance in colon cancer cells by activating STAT3

    LIANLI NI1,2,#, YUN YU1,2,#, HAN LIN1,2, WEISHAN ZHUGE2, LU TAO2, YIWEI SHEN2, RI CUI2,*, SHAOTANG LI1,2,*

    BIOCELL, Vol.47, No.10, pp. 2245-2254, 2023, DOI:10.32604/biocell.2023.030147

    Abstract Background: Homeobox B8 (HOXB8), a member of HOX family, plays a key role in the development of colorectal cancer (CRC). However, the function of HOXB8 in oxaliplatin (OXA) resistance in CRC is still unclear. This study investigated the role and precise molecular mechanism of HOXB8 in OXA-resistant CRC cells. Methods: The cell viability was measured by the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay, and the colony forming ability was determined by colony formation assay. The silencing RNA (siRNA) approach was used to knockdown HOXB8 in CRC cells while the lentiviral transfection system was used to establish… More >

  • Open Access

    ARTICLE

    The AKT/GSK3β-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1

    Wei Wei*1, Xiao-Dong Ma†1, Guan-Min Jiang, Bin Shi§, Wen Zhong, Chun-Lei Sun§, Liang Zhao*, Yan-Jiao Hou*, Hao Wang*

    Oncology Research, Vol.28, No.4, pp. 423-438, 2020, DOI:10.3727/096504020X15877284857868

    Abstract Although oxaliplatin serves as one of the first-line drugs prescribed for treating colorectal cancer (CRC), the therapeutic effect is disappointing due to drug resistance. So far, the molecular mechanisms mediating oxaliplatin resistance remain unclear. In this study, we found the chemoresistance in oxaliplatin-resistant HCT116 cells (HCT116/OXA) was mediated by the upregulation of ERCC1 expression. In addition, the acquisition of resistance induced epithelial–mesenchymal transition (EMT) as well as the Slug overexpression. On the contrary, Slug silencing reversed the EMT phenotype, decreased ERCC1 expression, and ameliorated drug resistance. Further mechanistical studies revealed the enhanced Slug expression resulted More >

  • Open Access

    ARTICLE

    Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy

    Ching-Wen Huang*, Cheng-Jen Ma*†, Wei-Chih Su*, Yi-Ting Chen‡§, Hsiang-Lin Tsai, Yung-Sung Yeh*#, Tsung-Kun Chang*, Wen-Hung Hsu**††, Fang-Jung Yu**††, Jaw-Yuan Wang*¶‡‡§§¶¶##

    Oncology Research, Vol.28, No.7-8, pp. 701-714, 2020, DOI:10.3727/096504020X15986099915822

    Abstract This study evaluated the survival effects of metronomic maintenance therapy with oral fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. We enrolled 197 patients with stage III CRC who had undergone radical resection and FOLFOX regimen adjuvant chemotherapy. The clinicopathological features and effects of metronomic maintenance therapy with oral capecitabine (daily dose of 850 mg/m2 , twice daily, on days 1–14 every 3 weeks for 6 months) on survival according to treatment group and EGFR expression were analyzed. By conducting an in vitro cell line study… More >

Displaying 1-10 on page 1 of 7. Per Page